AVVALACT

“Lactomezole, a safe and effective eradication therapy for H. Pylori without the use of antibiotics”

(E11089 AVVALACT – EUROSTARS/0716/01)

To develop a product, Lactomezole, as a new innovative standard of care for the management of dyspepsia and first line treatment for H. pylori infection, which is associated with dyspeptic and gastro-intestinal conditions, including gastric cancer. Lactomezole has significant OTC potential, as it will be the first proton pump inhibitor (PPI) plus prebiotic combo that has demonstrated eradication of H. pylori and normalization of GI tract microbiota without the use of antibiotics.

 

Consortium: AVVA Pharmaceuticals Ltd (HO), Cyprus University of Technology (PA1), ProtATonce (PA2)

Duration: 2017-2020

Total budget: €266,800

Funding Agency: The Project is co–funded by the European Regional Development Fund and the Republic of Cyprus through the Research & Innovation Foundation.